Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 19, 2024

Primary Completion Date

December 1, 2026

Study Completion Date

October 1, 2027

Conditions

Refractory Multiple MyelomaRelapsed Multiple Myeloma

Interventions

DRUG

Descartes-15

Autogolous T-cells expressing a chimeric antigen receptor directed to BCMA

Trial Locations (1)

Center for Cancer and Blood Disorders (AON), Bethesda